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Introduction
============

Melanoma is a potentially fatal form of skin cancer and its prognosis sharply declines from in situ (stage 0) to stage 4 \[[@REF1]\]. Current research focuses on prognostic factors and associations related to survival in melanoma, but such literature is often lacking for melanoma in situ (MIS) \[[@REF2]\]. Such studies have documented the gender-specific survival advantage of females in early stage (stage 1) melanoma \[[@REF3],[@REF4]\]. However, such investigation is lacking for MIS and for melanoma of the head and neck, the most common presenting location of melanomas \[[@REF5]\]. Herein, we utilize the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database to investigate the association of gender with survival in patients with MIS of the head and neck.

Materials and methods
=====================

We conducted a retrospective analysis using the SEER database, which provides data on approximately 34.6% of the United States population \[[@REF6]\]. Primary cases of MIS (1998-2015) were identified using the International Classification of Diseases for Oncology Third Edition (ICD-O-3) histological codes for MIS (8,720/2), MIS regressing (8,723/2), nodular MIS (8,721/2), balloon cell MIS (8,722/2), amelanotic MIS (8,730/2), MIS in junctional nevus (8,740/2), superficial spreading MIS (8,743/2), acral lentiginous MIS (8,744/2), desmoplastic MIS (8,745/2), mucosal lentiginous MIS (8,746/2), MIS in compound nevus (8,760/2), MIS in giant pigmented cell (8,761/2), epithelioid and spindle cell MIS (8,770/2), epithelioid cell MIS (8,771/2), and spindle cell MIS (8,772/2). Cases were extracted without \"malignant\" field selected in the SEER database with the designation \"/2,\" which reflects the following characteristics as per the SEER morphology classification: carcinoma in situ, intraepithelial, noninfiltrating, or noninvasive. ICD-O-3 topographical codes were further used to limit cases to the head and neck region, specifically as face and scalp or neck \[[@REF7]\]. Demographic, tumor, treatment, and survival characteristics were extracted. Univariate and multivariate Cox regression analyses were conducted to determine all-cause and cancer-specific mortality risks. SPSS software (version 25, IBM Corp., Armonk, NY) was used to conduct all statistical analyses. A P-value of \<0.05 was used to determine statistical significance.

Results
=======

A total of 9,881 cases of MIS of the head and neck were identified over a mean follow-up period of 76.6 (±57.0) months. Additionally, 68.7% (6,787/9,881) of the overall cohort were male. Demographic, tumor, and treatment characteristics are displayed in Table [1](#TAB1){ref-type="table"}. The 10-year overall survival (OS) was 79% for females, compared to 74% for males. After adjusting for demographic, tumor, and treatment data (found in Table [1](#TAB1){ref-type="table"}), male subjects demonstrated significantly poorer OS (hazard ratio \[HR\] 1.484; 95% confidence interval \[CI\] 1.332, 1.653; P\<0.001) and cancer-specific survival (HR 1.571; 95% CI 1.056, 2.338; P=0.026) compared to their female counterparts (Table [2](#TAB2){ref-type="table"}). The female subgroup is the reference group given its higher 10-year survival; thus, it is used as the reference for the Cox regression analysis, which necessitates comparison to a reference group to compute HRs for unadjusted and adjusted survival in males.

###### Demographic, tumor, and treatment characteristics of patients with melanoma in situ of the head and neck regions.

\*p \< 0.05.

MMS, Mohs micrographic surgery; WLE, wide local excision, LN, lymph node.

  ------------------------------------------------- ---------------------------------------- ------- ------------ ------- ------- --------- -------
                                                    Sex                                                                                     
  Female                                            Male                                     Total   Chi-square                             
  N                                                  %                                       N        %           N        %      P-value   
  Age group                                         0-64 years                               1429    46.2%        3066    45.2%   4495      45.5%
  65-74 years                                       731                                      23.6%   1845         27.2%   2576    26.1%      
  75+ years                                         934                                      30.2%   1876         27.6%   2810    28.4%      
  Race                                              White                                    2803    90.6%        6206    91.4%   9009      91.2%
  Black                                             7                                        0.2%    11           0.2%    18      0.2%       
  Other                                             25                                       0.8%    22           0.3%    47      0.5%       
  Unknown                                           259                                      8.4%    548          8.1%    807     8.2%       
  Hispanic ethnicity                                Non-Hispanic                             2981    96.3%        6647    97.9%   9628      97.4%
  Hispanic                                          113                                      3.7%    140          2.1%    253     2.6%       
  Marital status at diagnosis                       Married or domestic partner              1268    41.0%        3659    53.9%   4927      49.9%
  Single (never married)                            270                                      8.7%    476          7.0%    746     7.5%       
  Divorced‎/separated                               199                                      6.4%    201          3.0%    400     4.0%       
  Widowed                                           390                                      12.6%   203          3.0%    593     6.0%       
  Unknown                                           967                                      31.3%   2248         33.1%   3215    32.5%      
  Reporting source                                  Hospital inpatient‎/outpatient‎/clinic   1685    54.5%        3634    53.6%   5319      53.9%
  Physicians office‎/private medical practitioner   989                                      32.0%   2177         32.1%   3166    32.1%      
  Laboratory only                                   384                                      12.4%   889          13.1%   1273    12.9%      
  Other                                             34                                       1.1%    84           1.2%    118     1.2%       
  Primary site                                      Face                                     2552    82.5%        4928    72.6%   7480      75.7%
  Scalp‎/neck                                       542                                      17.5%   1859         27.4%   2401    24.3%      
  Laterality                                        Unilateral                               2450    79.2%        5049    74.4%   7499      75.9%
  Bilateral                                         5                                        0.2%    14           0.2%    19      0.2%       
  Not a paired site                                 447                                      14.4%   1380         20.3%   1827    18.5%      
  Midline                                           40                                       1.3%    79           1.2%    119     1.2%       
  Unknown                                           152                                      4.9%    265          3.9%    417     4.2%       
  Diagnostic confirmation                           Positive histology                       3075    99.4%        6744    99.4%   9819      99.4%
  Other                                             19                                       0.6%    43           0.6%    62      0.6%       
  Surgery type                                      WLE                                      1657    53.6%        3696    54.5%   5353      54.2%
  MMS                                               823                                      26.6%   1757         25.9%   2580    26.1%      
  No surgery                                        614                                      19.8%   1334         19.7%   1948    19.7%      
  LN biopsy                                         LN removed                               3       0.1%         16      0.2%    19        0.2%
  Sentinel LN biopsy                                8                                        0.3%    17           0.3%    25      0.3%       
  Both                                              1                                        0.0%    3            0.0%    4       0.0%       
  None                                              2396                                     77.4%   5369         79.1%   7765    78.6%      
  Unknown‎/NA                                       686                                      22.2%   1382         20.4%   2068    20.9%      
  Tumor size                                        \<1 cm                                   627     20.3%        1385    20.4%   2012      20.4%
  \>1 cm                                            8                                        0.3%    17           0.3%    25      0.3%       
  Unknown                                           2459                                     79.5%   5385         79.3%   7844    79.4%      
  Tumor ulceration                                  Not present                              1962    63.4%        4352    64.1%   6314      63.9%
  Present                                           8                                        0.3%    29           0.4%    37      0.4%       
  Unknown‎                                          1124                                     36.3%   2406         35.5%   3530    35.7%      
  ------------------------------------------------- ---------------------------------------- ------- ------------ ------- ------- --------- -------

###### Unadjusted and adjusted Cox regression analysis.

  --------------------- ---------------------- ------------------------- ---------------------- ----------- -----------
                        Overall survival       Cause-specific survival                                      
  HR (95% CI)           P-value                HR (95% CI)               P-value                            
  Unadjusted analysis   Female                 Reference                 Reference              Reference   Reference
  Male                  1.215 (1.098, 1.344)   \<0.001                   1.401 (0.964, 2.037)   0.077       
  Adjusted analysis     Female                 Reference                 Reference              Reference   Reference
  Male                  1.484 (1.332, 1.653)   \<0.001                   1.571 (1.056, 2.338)   0.026       
  --------------------- ---------------------- ------------------------- ---------------------- ----------- -----------

Discussion
==========

Improved melanoma survival for females has been reported in a large clinical trial and in European population-based studies \[[@REF8],[@REF9]\]. However, these findings, to our knowledge, have yet to be investigated for MIS. In our study, we focus on the most common location of MIS (head and neck) in order to report clinically relevant findings. In doing so, we demonstrate that male patients have worsened melanoma-specific survival for MIS of the head and neck. Several mechanisms may account for this finding.

In their population-based study of 11,734 melanoma patients, Joosse et al. revealed a significant female advantage for melanoma-specific survival, lower risk of cancer progression (including reduced risk of lymph node and visceral metastases), and survival advantage even after first progression, although another study found no difference in survival between males and females with regards to metastatic disease \[[@REF4],[@REF8]\]. To this end, they discussed the possibility of female gender-related factors that may portend a survival advantage or males may demonstrate a melanoma-stimulating factor \[[@REF8]\]. Similarly, Molife et al. suggested that gender may influence distinct factors implicated in phases of disease in melanoma, primarily local primary tumor invasion \[[@REF10]\]. Female steroids decrease invasion of melanoma cell lines through fibronectin, whereas male and adrenal steroids do not \[[@REF11],[@REF12]\]. This may influence progression from MIS to higher stage melanoma which would result in worsened prognosis and survival.

Additionally, males, compared to females, are less likely to self-detect melanomas, have lower perceptions of skin cancer risk, and are less often utilize healthcare providers \[[@REF1]\]. MIS represents an early detectable disease state that is readily-treated if care is sought early enough through self-detection or surveillance by a healthcare provider \[[@REF13],[@REF14]\]. As such, intrinsic healthcare behaviors factors may portend worsened survival in males with MIS serving as a surrogate for possibly other cancers at large \[[@REF14]\]. This may explain the worse male survival in seven different common malignancies presented by Molife et al. \[[@REF10]\]. Furthermore, our study assessed a cosmetically sensitive region-the head and neck. Al-Dujaili et al. demonstrated that women pay close attention to skin health, especially of the face, which is where skin cancers often manifest \[[@REF15]\]. This may lead to earlier detection and translate to cancer care-related behaviors portending improved outcomes

Conclusions
===========

The limitations of our study include its retrospective nature, possible upgrading of MIS diagnoses during the study period, miscoding, and inability to account of lifestyle, modifiable, and environmental risk factors. While cases were extracted strictly by SEER morphology codes, upgrading of malignancies could be possible and not accounted for during the time period of the survival analysis. Additionally, clinical practices vary by hospitals and facilities reporting to SEER. For instance, sentinal lymph node biopsy was performed for a small subset of our overall cohort. This practice is not commonplace for MIS disease. Nevertheless, this variable was included as part of our multivariate analysis along with a plethora of other variables in order to account for as many factors as possible.

Overall, MIS represents the earliest form of melanoma (stage 0), so identifying prognostic markers such as gender-specific differences in survival may heighten clinician awareness, influence patient counseling, and screening. Future studies would be well intended in identifying ways to mitigate gender-based disparities in melanoma survival.
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